Skip Navigation

AIDSInfo-at-a-glance

Issue No. 40 | September 18, 2012
A Service of the U.S. Department of Health and Human ServicesView HTML version
News and Features 

HHS Panel on Antiretroviral Guidelines for Adults and Adolescents Issues Statement on Use of Elvitegravir/Cobicistat/Tenofovir/Emtricitabine

The HHS Panel on Antiretroviral Guidelines for Adults and Adolescents recommends elvitegravir (EVG)/cobicistat (COBI)/tenofovir (TDF)/emtricitabine (FTC) as an alternative regimen for ART-naive patients. The fixed-dose combination product was recently approved by FDA. The Panel’s statement on use of EVG/COBI/TDF/FTC includes clinical trial and safety data on this combination product.

Home | Guidelines | Clinical Trials | Drugs | Health Topics | Education Materials | Mobile Resources & Tools
Unsubscribe | Contact Us
Left footer corner image Left footer corner image